SCHEDULE 13G/A: Rosalind Funds and Principals Disclose 7.7% Stake in InspireMD, Inc. via Amended SEC Filing

Rosalind Advisors, Inc., along with its associated funds and principals, has filed an amended Schedule 13G, disclosing a combined beneficial ownership of 7.7% in InspireMD, Inc., primarily through common shares and warrants.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P., Steven Salamon, and Gilad Aharon have filed an Amendment No. 7 to Schedule 13G regarding their beneficial ownership in InspireMD, Inc.
• As of March 31, 2025, Rosalind Advisors, Inc., Steven Salamon, and Gilad Aharon each beneficially own 9,713,171 shares, representing 7.7% of InspireMD, Inc.'s common stock.
• This 7.7% stake is based on 29,689,857 shares of common stock outstanding as of March 12, 2025, as reported in InspireMD's 10K filing.
• The beneficial ownership for Rosalind Advisors, Inc., Steven Salamon, and Gilad Aharon includes 2,274,990 common shares and 7,438,181 shares issuable upon the exercise of warrants.
• Rosalind Master Fund L.P. beneficially owns 8,057,171 shares (5.8%), comprising 1,722,990 common shares and 6,334,181 shares issuable from warrants.
• Rosalind Opportunities Fund I L.P. beneficially owns 1,656,000 shares (1.9%), comprising 552,000 common shares and 1,104,000 shares issuable from warrants.
• A "blocker provision" in the warrants prevents exercise if it would result in beneficial ownership exceeding 9.99% of the common stock, meaning the reporting persons were unable to exercise any warrants as of the filing event date.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of InspireMD, Inc.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates significant institutional investment in InspireMD, Inc., suggesting investor confidence. However, it's a routine disclosure and doesn't contain new operational or financial performance data.

Positives

• Increased transparency regarding significant institutional ownership in InspireMD, Inc.
• The investment by Rosalind Advisors and its funds indicates a vote of confidence from institutional investors.

Negatives

• The blocker provision on warrants limits the immediate conversion of potential shares, which could affect the reporting persons' ability to increase their stake beyond 9.99% without further action.

Risks

• The "blocker provision" in the warrants prevents the reporting persons from exercising warrants if it would lead to beneficial ownership exceeding 9.99% of the common stock, potentially limiting their ability to fully realize their warrant holdings or increase their stake.

Future Outlook

The document does not contain any forward-looking statements or guidance from InspireMD, Inc. It solely reports on the beneficial ownership stake of the reporting persons.

Industry Context

This filing reflects a routine disclosure of significant institutional ownership in a publicly traded company. For the medical device or healthcare industry, such filings indicate continued investor interest and capital allocation towards companies like InspireMD, Inc., which specializes in medical devices.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence in the company.
• Company Management: Awareness of a large institutional holder, which may influence future engagement or strategic decisions.

Next Steps

• The document does not outline any specific future actions, events, or milestones for InspireMD, Inc. or the reporting persons beyond the ongoing holding of their investment.

Key Dates

Keywords

InspireMD Inc., NSPR, Schedule 13G, Beneficial Ownership, Institutional Investor, Rosalind Advisors, Warrants, Common Shares, SEC Filing, Investment Fund